drugset / Trial / NCT02880293
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
NaSingle-groupOpen-labelTreatment
Summary
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Timeline
- Start
- 2016-08-23
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 40 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Background | Tacrolimus | Small molecule | — | — |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | — |